Peer-reviewed veterinary case report
Toxic side effects of combined chemo in dogs with bone cancer
By Bracha, S et al.·Published in The Journal of small animal practice·2014·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma.
- Species:
- dog
Plain-English summary
A group of 30 dogs with osteosarcoma (a type of bone cancer) underwent surgery and received chemotherapy to treat their condition. They were given either a combination of carboplatin and a metronomic treatment (low-dose continuous therapy) or carboplatin alternating with doxorubicin (another chemotherapy drug) along with metronomic therapy. While both treatment plans had similar survival times, the dogs receiving only carboplatin with metronomic therapy experienced more severe side effects. Overall, the study suggests that metronomic chemotherapy can be safely combined with traditional chemotherapy, but pet owners should be aware of the potential for increased toxicity.
People also search for: dog osteosarcoma treatment · chemotherapy side effects in dogs · piroxicam for dog cancer
Abstract
OBJECTIVE: To evaluate the tolerability of a piroxicam and cyclophosphamide metronomic treatment protocol combined with carboplatin alone or carboplatin and doxorubicin at maximal-tolerated doses. METHODS: Retrospective study of 30 dogs diagnosed with osteosarcoma. All dogs underwent amputation and chemotherapy treatment with one of the two maximal-tolerated dose protocols. Metronomic chemotherapy was administered in conjunction with these protocols, and continued subsequently. The protocols included 0 · 3 mg/kg piroxicam and 10 to 12 mg/M(2) cyclophosphamide with 300 mg/M(2) carboplatin alone, or 300 mg/M(2) carboplatin alternating with 30 mg/M(2) doxorubicin. RESULTS: Fourteen dogs were treated with the carboplatin and metronomic protocol and 16 were treated with the carboplatin alternating with doxorubicin and metronomic protocol. Grades 3 and 4 toxicities overall were significantly (P = 0 · 018) more common in the former group. The disease-free interval of the carboplatin and metronomic group was 192 days, which was not significantly different (P = 0 · 916) to the 182 days for the carboplatin alternating with doxorubicin and metronomic group. The median survival times of the two groups were 217 and 189 days, respectively. CLINICAL SIGNIFICANCE: Piroxicam and cyclophosphamide metronomic protocols can be safely administered in combination with maximal-tolerated dose chemotherapy protocols. A significantly higher frequency of toxicities was observed in dogs treated with the carboplatin and metronomic protocol.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24803081/